(R)-3-tert-butoxypropane-1,2-diol | 32455-37-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油脂
• 英文名称: (R)-3-tert-butoxypropane-1,2-diol
• 英文别名: (2R)-3-[(2-methylpropan-2-yl)oxy]propane-1,2-diol
• CAS: 32455-37-1
• 化学式: C₇H₁₆O₃
• 分子量: 148.202
• InChiKey: JPWDLYMEUNBLIR-ZCFIWIBFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (R)-3-tert-butoxypropane-1,2-diol 、 苯甲酰氯 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成
  参考文献：
  名称：

  Vicinal Diboronates in High Enantiomeric Purity through Tandem Site-Selective NHC−Cu-Catalyzed Boron−Copper Additions to Terminal Alkynes

  摘要：

  A Cu-catalyzed protocol for conversion of terminal alkynes to enantiomerically enriched diboronates is reported. In a single vessel, a site-selective hydroboration of an alkyne leads to the corresponding terminal vinylboronate, which undergoes a second site-selective and enantioselective hydroboration. Reactions proceed in the presence of 2 equiv of commercially available bis(pinacolato)diboron [B-2(pin)(2)] and 5-7.5 mol % loading of a chiral bidentate imidazolinium salt, affording diboronates in 60-93% yield and up to 97.5:2.5 enantiomeric ratio (er). The enantiomerically enriched products can be functionalized to afford an assortment of versatile organic molecules. Enynes are converted to unsaturated diboronates with high chemo- (>98% reaction of alkyne; <2% at alkene) and enantioselectivity (e.g., 94.5:5.5 er).

  DOI：

  10.1021/ja9089928
• 作为产物：
  描述：

  (R)-2-(3-tert-butoxy-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 在 双氧水 、 sodium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 0.33h， 生成 (R)-3-tert-butoxypropane-1,2-diol
  参考文献：
  名称：

  Vicinal Diboronates in High Enantiomeric Purity through Tandem Site-Selective NHC−Cu-Catalyzed Boron−Copper Additions to Terminal Alkynes

  摘要：

  A Cu-catalyzed protocol for conversion of terminal alkynes to enantiomerically enriched diboronates is reported. In a single vessel, a site-selective hydroboration of an alkyne leads to the corresponding terminal vinylboronate, which undergoes a second site-selective and enantioselective hydroboration. Reactions proceed in the presence of 2 equiv of commercially available bis(pinacolato)diboron [B-2(pin)(2)] and 5-7.5 mol % loading of a chiral bidentate imidazolinium salt, affording diboronates in 60-93% yield and up to 97.5:2.5 enantiomeric ratio (er). The enantiomerically enriched products can be functionalized to afford an assortment of versatile organic molecules. Enynes are converted to unsaturated diboronates with high chemo- (>98% reaction of alkyne; <2% at alkene) and enantioselectivity (e.g., 94.5:5.5 er).

  DOI：

  10.1021/ja9089928

文献信息

• Structure-Guided Regulation in the Enantioselectivity of an Epoxide Hydrolase to Produce Enantiomeric Monosubstituted Epoxides and Vicinal Diols via Kinetic Resolution
  作者：Die Hu、Bo-Chun Hu、Xiao-Dong Hou、Dong Zhang、Yu-Qing Lei、Yi-Jian Rao、Min-Chen Wu

  DOI：10.1021/acs.orglett.1c04348

  日期：2022.3.11

  Structure-guided microtuning of an Aspergillus usamii epoxide hydrolase was executed. One mutant, A214C/A250I, displayed a 12.6-fold enhanced enantiomeric ratio (E = 202) toward rac-styrene oxide, achieving its nearly perfect kinetic resolution at 0.8 M in pure water or 1.6 M in n-hexanol/water. Several other beneficial mutants also displayed significantly improved E values, offering promising biocatalysts

  对Aspergillus usamii环氧水解酶进行了结构引导的微调。一种突变体 A214C/A250I对消旋-氧化苯乙烯的对映体比 ( E = 202)提高了 12.6 倍，在纯水中 0.8 M 或正己醇/水中 1.6 M 时实现了近乎完美的动力学分辨率。其他一些有益的突变体也显示出显着提高的E值，为获得 19 种结构多样的手性单取代环氧化物（97.1 – ≥ 99% ee s）和邻二醇（56.2–98.0% ee p）提供了有希望的生物催化剂，并且产率很高。
• FORMATION OF MACROMOLECULES USING ITERATIVE GROWTH AND RELATED COMPOUNDS
  申请人：Massachusetts Institute of Technology

  公开号：US20160272623A1

  公开（公告）日：2016-09-22

  In some embodiments, macromolecules and related methods are provided. In some embodiments, an iterative growth process may be used to form a macromolecule comprising one or more repeat units comprising a functionalizable pendant group, with precise control over mass, length, backbone sequence, pendant group sequence, and/or stereochemistry, amongst other features. Macromolecules (e.g., non-natural macromolecules) form from the iterative growth process, described herein, may be used for a wide variety of applications, including the delivery of active agents.

  在某些实施例中，提供了大分子和相关方法。在某些实施例中，可以使用迭代生长过程来形成包含一个或多个可官能化挂基的重复单元的大分子，具有对质量、长度、骨架序列、挂基序列和/或立体化学等特征的精确控制。从这里描述的迭代生长过程中形成的大分子（例如，非天然大分子）可用于各种应用，包括传递活性剂。
• N-SUBSTITUTED AZAINDOLES AND METHODS OF USE
  申请人：Dyke Hazel Joan

  公开号：US20100216768A1

  公开（公告）日：2010-08-26

  The invention relates to N-substituted azaindolyl compounds of Formula I with anti-cancer and/or anti-inflammatory activity and more specifically to N-substituted azaindolyl compounds which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

  该发明涉及具有抗癌和/或抗炎活性的Formula I的N-取代吲哚基化合物，更具体地涉及抑制MEK激酶活性的N-取代吲哚基化合物。该发明提供了用于抑制异常细胞生长或治疗哺乳动物体内过度增殖疾病或治疗炎症性疾病的组合物和方法。该发明还涉及使用这些化合物进行哺乳动物细胞的体外、体内和体内诊断或治疗，或相关病理条件的方法。
• PROCESS FOR THE PREPARATION OF (S)-4-FLUOROMETHYL-DIHYDRO-FURAN-2-ONE
  申请人：Zutter Ulrich

  公开号：US20080108816A1

  公开（公告）日：2008-05-08

  The present invention relates to a process of the preparation of (S)-4-fluoromethyl-dihydro-furan-2-one of the formula by employing a dialkylmalonate of the formula wherein R 1b is lower alkyl, and the use of this process for the manufacture of DPP-IV inhibitors that are useful for the treatment and/or prophylaxis of diseases such as diabetes.

  本发明涉及一种制备(S)-4-氟甲基二氢呋喃-2-酮的方法，该方法采用式为其中R1为低级烷基的二烷基丙二酸酯，并且利用该方法制造DPP-IV抑制剂，该抑制剂可用于治疗和/或预防糖尿病等疾病。
• BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS
  申请人：Heald Robert Andrew

  公开号：US20110190257A1

  公开（公告）日：2011-08-04

  The invention relates to bicyclic heterocycles of formulae I and II with anti-cancer and/or anti-inflammatory activity and more specifically with MEK kinase inhibitory activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth, treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

  本发明涉及公式I和II的双环杂环化合物，具有抗癌和/或抗炎活性，更具有MEK激酶抑制活性。 本发明提供了用于抑制异常细胞生长，治疗增殖过度性疾病或治疗哺乳动物的炎症性疾病的组合物和方法。 本发明还涉及使用该化合物进行哺乳动物细胞的体外，体内和原位诊断或治疗，或相关病理情况的方法。